Science & Tech

Trump Directs HHS to Pursue 'Gold Standard' Childhood Vaccine Guidance, Urging Separate MMR Shots

On Aug. 10, Trump signed an order directing HHS to pursue 'Gold Standard' childhood vaccine guidance, urging separate MMR shots — but courts and availability limit immediate change.

#vaccines, #publichealth, #trump, #hhs

Radioligand 177Lu-PSMA-617 Delays Radiographic Progression in PSMA-Positive Hormone-Sensitive Metastatic Prostate Cancer, Phase 3 Trial Shows

Phase 3 PSMAddition trial found 177Lu‑PSMA‑617 added to hormonal therapy reduced risk of radiographic progression in PSMA‑positive mHSPC.

#prostatecancer, #radioligandtherapy, #pluvicto, #clinicaltrials

FDA Grants Accelerated Approval to Replimune’s Tudriqev for PD-1–Resistant Advanced Melanoma

FDA gives accelerated approval to Replimune’s Tudriqev with nivolumab for adults with PD‑1–resistant unresectable advanced melanoma; confirmatory trials required.

$RPLM, #melanoma, #fda, #oncology, #replimune, #drugapproval

UK regulator warns hospitals to check Dräger Atlan anaesthesia workstations after expanded safety action

Britain's MHRA on Aug. 4 told hospitals to check Dräger Atlan anaesthesia workstations after an expanded safety action over a ventilator motor defect.

#medicaldevices, #patient-safety, #drager, #mhra

Pfizer says Phase 3 LITFULO trials met key vitiligo endpoints; plans global regulatory filings

Pfizer said Phase 3 trials of LITFULO (ritlecitinib) met key endpoints in nonsegmental vitiligo across 2,174 patients, and it plans global regulatory filings.

$PFE, #pfizer, #vitiligo, #ritlecitinib

EU Authorizes Pfizer-BioNTech XFG-Adapted COVID-19 Vaccine for Ages 6 Months and Up

EU clears Pfizer and BioNTech’s 2026–27 XFG-adapted COVID-19 vaccine for people 6 months and older ahead of the 2026–27 respiratory season.

#covid19, #vaccine, #pfizer, #biontech, #xfg

Deramiocel improves arm function and cardiac measures in phase 3 trial as FDA advisory panel reviews Capricor's application

Phase 3 trial of deramiocel (CAP-1002) showed significant benefits on upper-limb function and cardiac measures; FDA advisory panel is reviewing the data.

$CAPR, #duchenne, #muscular-dystrophy, #biotech, #fda

19-Protein Blood Panel Estimates When People with ALS-Linked Genes May Become Symptomatic

An NIH-backed study found a 19-protein blood panel predicts when carriers of ALS-linked variants may develop symptoms, with about an 18-month average error.

#health, #als, #biomarkers, #neurology

FDA Approves Lipfendra, Merck’s First Oral PCSK9 Inhibitor, to Lower LDL in Adults

FDA approves Merck's Lipfendra (enlicitide), the first oral PCSK9 inhibitor, for adults with hypercholesterolemia as a once-daily LDL-lowering pill.

$MRK, #merck, #lipfendra, #pcsk9, #cholesterol

WHO updates dementia guidance, says up to 45% of risk linked to modifiable factors

WHO's new guidelines recommend exercise, social engagement, hearing aids and less air pollution — and advise against routine vitamins or supplements to lower dementia risk.

#dementia, #who, #publichealth, #cognitivehealth

One-month dual antithrombotic strategy after PCI reduced bleeding without higher 12‑month thromboembolic risk in OPTIMA‑AF trial

OPTIMA‑AF found that stopping dual antithrombotic therapy after one month and continuing a DOAC alone reduced bleeding without raising 12‑month death or thromboembolism.

#cardiology, #atrialfibrillation, #pci, #anticoagulation

WHO: Bundibugyo Ebola Outbreak in eastern DRC ‘evolving rapidly’ as cases spread into Uganda

WHO warns Bundibugyo Ebola outbreak in eastern DRC is 'evolving rapidly' with many cases unlinked; cross-border spread into Uganda complicates response.

#ebola, #drc, #uganda, #who

GAO: Federal ACA Marketplace Still Leaves Consumers Vulnerable to Unauthorized Enrollments

GAO finds rising unauthorized ACA enrollments and plan switches, urging CMS to strengthen consent checks, access limits and consumer notices.

#healthcare, #aca, #cms, #gao

Pirtobrutinib Triplet Prolongs Progression-Free Survival in Previously Treated CLL, Lancet Reports

Phase 3 BRUIN CLL-322 found fixed-duration pirtobrutinib with venetoclax–rituximab cut progression/death risk by ~45% vs venetoclax–rituximab in relapsed CLL.

$LLY, #cancer, #cll, #hematology, #pirtobrutinib

WHO Projects Global Cancer Cases Could Reach Nearly 35 Million by 2050, Warns of Growing Inequities

WHO projects new cancer cases from 20.6M (2024) to nearly 35M by 2050, warning low-income countries will bear the heaviest burden without stronger prevention.

#cancer, #who, #globalhealth, #publichealth